SMi’s 3rd Annual Conference

Superbugs & Superdrugs USA 
November 12 – 13, 2018 | Iselin, New Jersey

The issue of antibacterial resistance is becoming increasingly prevalent within the world of modern medicine. Difficult-to-treat pathogens create an incredibly real issue within clinical environments; and the problem needs to be addressed with novel treatments and the development of mechanisms which circumvent current therapeutic barriers.The push to commercialization of novel anti-infectives is also a big barrier to market entry within the field; with red-tape and funding restrictions creating hindrances to the progress of anti-infective drugs through trial and regulatory approvals processes.

To address the ever-growing need of informative and thought provoking discussion, in order to address these industry issues, Superbugs & Superdrugs USA conference will offer a jam-packed agenda with presentations from key industry leaders and up-and-coming thinkers, within the field.

Register to attend by September 28 to save $100 on booking fee
“While recently approved antibiotic agents will likely help stem AMR crisis, novel approaches to the prevention and treatment of MDR infections are needed to ensure a viable antimicrobial armamentarium for the future.
The SMi’s Superbugs & Superdrugs USA meeting will bring together expertise from individuals in multiple disciplines in the field of infectious disease representing research, regulatory, funding, diagnostics and academia to focus on supporting antimicrobial research and development, funding opportunities and resources for companies, new diagnostics for clinical applications, as well as novel therapies and approaches”

William J. Weiss – UNT System College of Pharmacy
A. Simon Lynch – Janssen Research & Development

For more information, please visit:

Comments are closed.

%d bloggers like this: